



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Anti-JAM-A [6F4] Standard Size Ab03260-10.0

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format for improved compatibility with existing reagents assays and techniques.

**Isotype and Format:** Human IgG1, Kappa

**Clone Number:** 6F4

**Alternative Name(s) of Target:** CD321; JAM-1; JAM1; JCAM; F11R; PAM-1; Junctional adhesion molecule A; Junctional adhesion molecule 1; Platelet F11 receptor

**UniProt Accession Number of Target Protein:** Q9Y624

**Published Application(s):** WB, ELISA, FC, IF, IHC

**Published Species Reactivity:** Human

**Immunogen:** The original antibody was generated by immunizing BALB/c mice with MCF-7 cells. The humanized version was generated by grafting CDRs of parental mouse antibody onto human framework regions.

**Specificity:** This antibody specifically recognizes human junctional adhesion molecule A and does not cross-react with other members of the JAM family. JAM-A is an adherens and tight junction protein expressed by endothelial and epithelial cells. It is recently identified as an antigenic protein (Ag) overexpressed in tumor cells and associated with cancer progression.

**Application Notes:** This antibody was used for the characterization of human junctional adhesion molecule-A (JAM-A) and study of its expression on various cancerous tissues. The binding specificity of this antibody for human JAM-A expressed on CHO cells was confirmed using flow cytometry. JAM-A expression level on cell surface was determined by immunofluorescence staining and visualized by confocal microscopy. This antibody can also be used in the determination of JAM-A protein using western blot. Immunohistochemical analysis using this antibody revealed that JAM-A is overexpressed on breast, lung and kidney tumor tissues. Injections of anti-JAM-A antibody resulted in a significant tumor growth inhibition of xenograft human tumors in vivo. Treatment with monoclonal antibody induced a decrease of the Ki67 expression and downregulated JAM-A levels. This antigen may play a role in interfering with tumor proliferation (PMID: 22886345). This antibody binds the extracellular domain of JAM-A in an ELISA (Goetsch et al, 2011).

**Antibody First Published in:** Goetsch et al. A novel role for junctional adhesion molecule-A in tumor proliferation: modulation by an anti-JAM-A monoclonal antibody. *Int J Cancer*. 2013 Mar 15;132(6):1463-74.

[PMID:22886345](#)

**Note on publication:** Describes the characterization of a new target expressed on cancerous tissues using this antibody,

## Product Form

**Size:** 200 µg Purified antibody.

**Purification:** Protein A affinity purified

**Supplied In:** PBS with 0.02% Proclin 300.

**Storage Recommendation:** Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.